These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 26960282)

  • 21. Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas.
    Fallon KB; Palmer CA; Roth KA; Nabors LB; Wang W; Carpenter M; Banerjee R; Forsyth P; Rich K; Perry A
    J Neuropathol Exp Neurol; 2004 Apr; 63(4):314-22. PubMed ID: 15099021
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic significance of relative 1p/19q codeletion in oligodendroglial tumors.
    Chamberlain MC; Born D
    J Neurooncol; 2015 Nov; 125(2):249-51. PubMed ID: 26341371
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chromosome 1p/19q status combined with expression of p53 protein improves the diagnostic and prognostic evaluation of oligodendrogliomas.
    Xiong J; Liu Y; Wang Y; Ke RH; Mao Y; Ye ZR
    Chin Med J (Engl); 2010 Dec; 123(24):3566-73. PubMed ID: 22166632
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations.
    Figarella-Branger D; Mokhtari K; Dehais C; Jouvet A; Uro-Coste E; Colin C; Carpentier C; Forest F; Maurage CA; Vignaud JM; Polivka M; Lechapt-Zalcman E; Eimer S; Viennet G; Quintin-Roué I; Aubriot-Lorton MH; Diebold MD; Loussouarn D; Lacroix C; Rigau V; Laquerrière A; Vandenbos F; Michalak S; Sevestre H; Peoch M; Labrousse F; Christov C; Kemeny JL; Chenard MP; Chiforeanu D; Ducray F; Idbaih A;
    Neuro Oncol; 2014 Sep; 16(9):1244-54. PubMed ID: 24723566
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and histological characteristics of recurrent oligodendroglial tumors: comparison between primary and recurrent tumors in 18 cases.
    Kanamori M; Kumabe T; Shibahara I; Saito R; Yamashita Y; Sonoda Y; Suzuki H; Watanabe M; Tominaga T
    Brain Tumor Pathol; 2013 Jul; 30(3):151-9. PubMed ID: 23053495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ancillary FISH analysis for 1p and 19q status: preliminary observations in 287 gliomas and oligodendroglioma mimics.
    Perry A; Fuller CE; Banerjee R; Brat DJ; Scheithauer BW
    Front Biosci; 2003 Jan; 8():a1-9. PubMed ID: 12456321
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Extent of resection, molecular signature, and survival in 1p19q-codeleted gliomas.
    Garton ALA; Kinslow CJ; Rae AI; Mehta A; Pannullo SC; Magge RS; Ramakrishna R; McKhann GM; Sisti MB; Bruce JN; Canoll P; Cheng SK; Sonabend AM; Wang TJC
    J Neurosurg; 2021 May; 134(5):1357-1367. PubMed ID: 32384274
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Diagnostic and prognostic roles of loss of CIC protein expression in oligodendroglial tumors].
    Liu CC; Zhang LY; Wang LM; Wang DD; Fu YJ; Cai YN; Lu DH; Piao YS
    Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):679-683. PubMed ID: 29050068
    [No Abstract]   [Full Text] [Related]  

  • 29. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
    Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
    Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
    Appay R; Dehais C; Maurage CA; Alentorn A; Carpentier C; Colin C; Ducray F; Escande F; Idbaih A; Kamoun A; Marie Y; Mokhtari K; Tabouret E; Trabelsi N; Uro-Coste E; Delattre JY; Figarella-Branger D;
    Neuro Oncol; 2019 Dec; 21(12):1519-1528. PubMed ID: 31832685
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recurrent oligodendroglioma with changed 1p/19q status.
    Barresi V; Mafficini A; Calicchia M; Piredda ML; Musumeci A; Ghimenton C; Scarpa A
    Neuropathology; 2022 Apr; 42(2):160-166. PubMed ID: 35144313
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alpha-internexin and altered CIC expression as a supportive diagnostic marker for oligodendroglial tumors with the 1p/19q co-deletion.
    Nagaishi M; Suzuki A; Nobusawa S; Yokoo H; Nakazato Y
    Brain Tumor Pathol; 2014 Oct; 31(4):257-64. PubMed ID: 24197863
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation between genetic alteration and long-term clinical outcome of patients with oligodendroglial tumors, with identification of a consistent region of deletion on chromosome arm 1p.
    Hashimoto N; Murakami M; Takahashi Y; Fujimoto M; Inazawa J; Mineura K
    Cancer; 2003 May; 97(9):2254-61. PubMed ID: 12712480
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Utility of targeted next-generation sequencing assay to detect 1p/19q co-deletion in formalin-fixed paraffin-embedded glioma specimens.
    Pallavajjala A; Haley L; Stinnett V; Adams E; Pallavajjala R; Huang J; Morsberger L; Hardy M; Long P; Gocke CD; Eshleman JR; Rodriguez FJ; Zou YS
    Hum Pathol; 2022 Aug; 126():63-76. PubMed ID: 35561840
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mitotic index, microvascular proliferation, and necrosis define 3 pathological subgroups of prognostic relevance among 1p/19q co-deleted anaplastic oligodendrogliomas.
    Figarella-Branger D; Mokhtari K; Dehais C; Carpentier C; Colin C; Jouvet A; Uro-Coste E; Forest F; Maurage CA; Vignaud JM; Polivka M; Lechapt-Zalcman E; Eimer S; Viennet G; Quintin-Roué I; Aubriot-Lorton MH; Diebold MD; Loussouarn D; Lacroix C; Rigau V; Laquerrière A; Vandenbos F; Michalak S; Sevestre H; Peoch M; Labrousse F; Christov C; Kemeny JL; Chenard MP; Chiforeanu D; Ducray F; Idbaih A; Delattre JY;
    Neuro Oncol; 2016 Jun; 18(6):888-90. PubMed ID: 27175000
    [No Abstract]   [Full Text] [Related]  

  • 36. Codeletions at 1p and 19q predict a lower risk of pseudoprogression in oligodendrogliomas and mixed oligoastrocytomas.
    Lin AL; Liu J; Evans J; Leuthardt EC; Rich KM; Dacey RG; Dowling JL; Kim AH; Zipfel GJ; Grubb RL; Huang J; Robinson CG; Simpson JR; Linette GP; Chicoine MR; Tran DD
    Neuro Oncol; 2014 Jan; 16(1):123-30. PubMed ID: 24285548
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1.
    Cahill DP; Louis DN; Cairncross JG
    CNS Oncol; 2015; 4(5):287-94. PubMed ID: 26545048
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alpha Internexin: A Surrogate Marker for 1p/19q Codeletion and Prognostic Marker in Anaplastic (WHO grade III) Gliomas.
    Rajmohan KS; Sugur HS; Shwetha SD; Pandey P; Arivazhagan A; Santosh V
    Neurol India; 2020; 68(4):832-837. PubMed ID: 32859823
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Co-deletion of 1p/19q as Prognostic and Predictive Biomarker for Patients in West Bohemia with Anaplastic Oligodendroglioma.
    Polivka J; Polivka J; Repik T; Rohan V; Hes O; Topolcan O
    Anticancer Res; 2016 Jan; 36(1):471-6. PubMed ID: 26722084
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular imaging of 1p/19q deletion in oligodendroglial tumours with 11C-methionine positron emission tomography.
    Iwadate Y; Shinozaki N; Matsutani T; Uchino Y; Saeki N
    J Neurol Neurosurg Psychiatry; 2016 Sep; 87(9):1016-21. PubMed ID: 26848169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.